Posts

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

on
Eli Lilly announced a deal to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, with potential additional milestone payments totaling up to $3.8 billion. The acquisition gives Lilly access to AtaiBeckley's advanced psychedelic-based mental health therapies, including its lead intranasal 5-MeO-DMT candidate BPL-003 for treatment-resistant depression now in Phase 3 trials. Lilly will pay $6.75 per share in cash, representing a roughly 26% premium to AtaiBeckley’s prior closing price, plus up to $2.50 per share tied to development and regulatory milestones. The move marks Lilly's boldest entry yet into the psychedelic medicine space and is part of a broader acquisition spree in 2026 leveraging profits from its GLP-1 business. The companies expect the deal to close in the third quarter, pending regulatory and shareholder approvals. Sources: Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion Lilly buys AtaiBeckley for $2.8B upfront to challenge ...

Biopharma Bites: Boehringer’s 2Q, Keytruda Expansion, and Wegovy’s Market Domination

on

Brain implants that restore touch pass decade-long safety test

on

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on

Bipartisan Senate bill seeks to build vigilance around foreign companies making drugs in US

on

Eli Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J in psychedelic mental health market

on

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

on

Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger | ADVC001 lead-212 PSMA-targeted therapy and manufacturing expansion

on

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first

on

Q32 Bio Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants

on

Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

on

Spravato Sales Surge and Growing Psychedelic Competition, 2026

on

Veradermics stock jumps on encouraging data for oral hair loss option in women

on